Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 6/20 | 0.53 |
| ▸ | ACE | P12821 | 5/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.51 |
| ▸ | F2R | P25116 | 2/20 | 0.51 |
| ▸ | CTSD | P07339 | 2/20 | 0.51 |
| ▸ | CTSE | P14091 | 2/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.49 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.49 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29666880 | 0.90 | OPRK1 (0.58) | OPRK1ACEACE2NMUR2NMUR1 | |
| SCHEMBL29666769 | 0.90 | ACE (0.58) | ACEACE2 | |
| SCHEMBL29666805 | 0.90 | CALCRL (0.55) | OPRK1ACEACE2 | |
| SCHEMBL29666745 | 0.89 | ACE (0.58) | ACEACE2 | |
| SCHEMBL29666860 | 0.88 | ACE (0.57) | OPRK1ACEACE2REN | |
| SCHEMBL30785955 | 0.86 | ACE (0.56) | OPRK1ACEACE2 | |
| SCHEMBL30203894 | 0.86 | NMUR2 (0.54) | OPRK1NMUR2NMUR1 | |
| SCHEMBL29666711 | 0.85 | ACE (0.59) | OPRK1ACEACE2 | |
| SCHEMBL29666878 | 0.85 | ACE (0.58) | ACEACE2 | |
| SCHEMBL29666773 | 0.84 | ACE (0.59) | ACEACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122721-A2 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | OREGON STATE UNIVERSITY (US) | 2023-06-29 | — | — | WO | claimed |
| US-20240343760-A1 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | OREGON STATE UNIVERSITY (OR) | 2024-10-17 | — | — | US | disclosed |
| WO-2023122721-A2 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | OREGON STATE UNIVERSITY (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343760-A1 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | ARGLU1, TPX2, RXFP1 | OPRK1 1864/4885ACE 3897/4885ACE2 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.